News | August 05, 2013

Thubrikar’s TAVI System Surpasses ISO Requirement for Durability

The Optimum TAV is a treatment option for aortic stenosis

August 5, 2013 — Thubrikar Aortic Valve’s Optimum TAV, transcatheter aortic valve implantation (TAVI) system, has surpassed 200 million cycles in an ongoing durability test — which simulates over five years in humans and meets the requirement set by the International Organization for Standardization (ISO) — in a third party GLP study.

The company previously demonstrated feasibility of its Optimum TAV and delivery catheters in eight acute and chronic sheep. It has filed patents for its Optimum TAV and catheters, and has accomplished all of these milestones within $1 million.

The Optimum TAV is a low-profile, bovine pericardial, self-expanding percutaneous valve that is a heart valve treatment option for aortic stenosis. Optimum TAV was designed to mimic the natural aortic valve, improve durability and to be used in valve-in-valve procedures and bicuspid patients.

For more information:

Related Content

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
heart valve regurgitation seen on an echocardiogram, cardiac ultrasound, from ASE study
News | Cardiovascular Ultrasound| June 16, 2017
June 15, 2017 – While much attention has been focused on ways to lower heart disease-related injuries and deaths, the
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Sponsored Content | Videos | Heart Valve Technology| June 14, 2017
A discussion with Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at
FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Sapien 3 valve for VIV (valve in valve) procedures cleared by FDA
Feature | Heart Valve Technology| June 06, 2017 | Dave Fornell
The U.S. Food and Drug Administration (FDA) has granted market clearance for aortic and mitral valve-in-valve...
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
News | Guidewires| May 30, 2017
A Canadian cardiologist has published a report in the journal Eurointervention describing how he used a Canadian-...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Overlay Init